Envestnet Asset Management Inc. increased its holdings in Organon & Co. (NYSE:OGN – Free Report) by 6.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,835 shares of the company’s stock after acquiring an additional 9,755 shares during the quarter. Envestnet Asset Management Inc. owned about 0.06% of Organon & Co. worth $3,453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Versant Capital Management Inc grew its stake in shares of Organon & Co. by 200.2% during the 2nd quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after purchasing an additional 805 shares during the period. Fidelis Capital Partners LLC purchased a new position in Organon & Co. during the 1st quarter valued at $43,000. Tompkins Financial Corp increased its stake in Organon & Co. by 450.7% in the 1st quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after buying an additional 1,974 shares during the period. Atlas Capital Advisors LLC raised its stake in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after acquiring an additional 2,147 shares in the last quarter. Finally, Hexagon Capital Partners LLC increased its stake in shares of Organon & Co. by 123.9% during the first quarter. Hexagon Capital Partners LLC now owns 2,628 shares of the company’s stock valued at $49,000 after buying an additional 1,454 shares during the period. Institutional investors own 77.43% of the company’s stock.
Organon & Co. Stock Performance
NYSE OGN opened at $18.58 on Thursday. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $23.10. The business’s 50-day moving average price is $20.68 and its 200 day moving average price is $20.15. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The firm has a market cap of $4.78 billion, a P/E ratio of 4.54, a P/E/G ratio of 0.87 and a beta of 0.85.
Organon & Co. Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were given a $0.28 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.12 annualized dividend and a dividend yield of 6.03%. Organon & Co.’s dividend payout ratio is presently 27.38%.
Wall Street Analysts Forecast Growth
OGN has been the subject of several analyst reports. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $21.00.
Check Out Our Latest Research Report on OGN
About Organon & Co.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Featured Articles
- Five stocks we like better than Organon & Co.
- How to Invest in the Best Canadian Stocks
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Retail Stocks Investing, Explained
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.